June 24, 2014 / 6:17 AM / 3 years ago

BRIEF-ThromboGenics to stay as stand-alone company, CFO to quit

1 Min Read

June 24 (Reuters) - ThromboGenics NV -

* Provides update on strategic review process

* Company to remain independent

* CFO and board member Chris Buyse to resign

* Company will provide a further update at time of its 2014 half year reporting on August 28

* Following an assessment of various strategic options including a sale of entire company, board of directors of ThromboGenics has decided to continue as a stand-alone company

* Chris Buyse, chief financial officer and board member of ThromboGenics, will resign effective June 30, 2014

* As of July 1, Luc Philips, former CFO of KBC Group, will take on the role of interim-CFO

* Has decided to continue as a stand-alone co; pursue discussions for a potential partnership for commercialization of Jetrea in the US Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below